Patents Examined by Stephen T Kapushoc
-
Patent number: 11649501Abstract: A method to predict an increased risk of a greater susceptibility to a metal implant sensitivity in a test person. The method includes providing an isolated sample with a genetic material of the test person, and examining a single nucleotide polymorphism rs1143627 SEQ?ID?NO:?1 AGCCTCCTACTTCTGCTTTTGAAAGC[C/T]ATAAAA ACAGCGAGGGAGAACTGG,? in a gene coding for interleukin 1 beta and ascertaining whether a C is present at a position of the single nucleotide polymorphism, and/or examining a VNTR polymorphism rs2234663 with the repeat SEQ?ID?NO:?2 ATCCTGGGGAAAGTGAGGGAAATATGGACATCACATGGAACAACAT CCAGGAGACTCAGGCCTCTAGGAGTAACTGGGTAGTGTGC, in a gene coding for a IL1 receptor antagonist, IL1-RN and ascertaining whether the repeat is present five times.Type: GrantFiled: February 4, 2019Date of Patent: May 16, 2023Assignee: KLINIKUM DER UNIVERSITAET MUENCHENInventors: Burkhard Summer, Peter Thomas, Sylvia Usbeck, Diana Lill
-
Patent number: 11629385Abstract: Provided herein are novel organoid culture media, organoid culture systems, and methods of culturing tumor organoids using the subject organoid culture media. Also provided herein are tumor organoids developed using such organoid culture systems, methods for assessing the clonal diversity of the tumor organoids, and methods for using such tumor organoids, for example, for tumor modelling and drug development applications. In particular embodiments, the tumor organoid culture media provided herein is substantially free of R-spondins (e.g., R-spondin1).Type: GrantFiled: November 22, 2019Date of Patent: April 18, 2023Assignee: Tempus Labs, Inc.Inventors: Ameen Salahudeen, Verónica Sánchez Freire, Brandon L. Mapes
-
Patent number: 11618925Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.Type: GrantFiled: January 31, 2020Date of Patent: April 4, 2023Assignee: Population Bio, Inc.Inventors: Eli Hatchwell, Peggy S. Eis
-
Patent number: 11613783Abstract: The present disclosure provides methods, systems, compositions, and kits for the high-throughput detection of multi-molecule biomarkers in a biological sample. The disclosed methods, systems, compositions, and kits utilize antibody-oligonucleotide tags to detect two or more molecules that are in close proximity.Type: GrantFiled: December 30, 2021Date of Patent: March 28, 2023Assignee: Tempus Labs, Inc.Inventor: Timothy Rand
-
Patent number: 11613782Abstract: The invention provides a gene signature for use in determining a likelihood of a latent tuberculosis (TB) infection in a subject transitioning to active TB disease. The gene signature comprises at least SEPT4 and BLK, and optionally also GAS6 and/or CD1C. Expression levels of these genes are detected in a sample from the subject, and the ratios of expression of at least two of the above genes are calculated (e.g. SEPT4:BLK, SEPT4:CD1C, GAS6:BLK and/or GAS6:CD1C). A score is assigned to each ratio, the score being indicative of the likelihood of the latent TB infection transitioning into active TB disease, based on the ratio for the respective gene pair. The subject can be identified as having a latent TB infection that is likely to transition into active TB disease or that is not likely to transition into active TB disease based on the score or on the average of the scores.Type: GrantFiled: March 13, 2019Date of Patent: March 28, 2023Assignees: UNIVERSITY OF CAPE TOWN, STELLENBOSCH UNIVERSITY, SEATTLE CHILDREN'S HOSPITAL, MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V, UNITED KINGDOM RESEARCH AND INNOVATIONInventors: Sara Suliman, Ethan Greene Thompson, Jayne Suzanne Sutherland, Stefan H. E. Kaufmann, Thomas Jens Scriba, Daniel Edward Zak, Gerhard Walzl
-
Patent number: 11591656Abstract: Compositions and methods for the detection and treatment of ADHD are provided.Type: GrantFiled: September 6, 2018Date of Patent: February 28, 2023Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventors: Hakon Hakonarson, Berta Almoguera, Lyam Vazquez, Patrick Sleiman
-
Patent number: 11578367Abstract: Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.Type: GrantFiled: October 8, 2019Date of Patent: February 14, 2023Assignee: Becton, Dickinson and CompanyInventors: James A. Garrett, Sha-Sha Wang, Keith Thornton, Richard L. Moore, William Keating, William A. Nussbaumer, Craig C. Whiteford
-
Patent number: 11542558Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample f a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: February 27, 2020Date of Patent: January 3, 2023Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Hiroko Sudo, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
-
Patent number: 11530447Abstract: The present invention is directed to methods and kits for determining the presence of a mutated SLC30A2 polynucleotide. The invention is further directed to methods of determining a subject's genetic-susceptibility to zinc deficiency and evaluating zinc levels in a composition comprising breast milk.Type: GrantFiled: April 11, 2018Date of Patent: December 20, 2022Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITEDInventors: Yehuda G. Assaraf, Yarden Golan Maor
-
Patent number: 11519927Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: February 25, 2020Date of Patent: December 6, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Hiroko Sudo, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
-
Patent number: 11519038Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: March 3, 2020Date of Patent: December 6, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Satoshi Kondou, Hitoshi Nobumasa, Satoko Kozono, Hiroko Sudo, Junpei Kawauchi, Takahiro Ochiya, Nobuyoshi Kosaka
-
Patent number: 11512355Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: February 7, 2020Date of Patent: November 29, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Satoshi Kondou, Hitoshi Nobumasa, Satoko Kozono, Hiroko Sudo, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
-
Patent number: 11499198Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: March 18, 2020Date of Patent: November 15, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Junpei Kawauchi, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Hiroko Sudo, Atsushi Ochiai, Motohiro Kojima
-
Patent number: 11486009Abstract: This invention relates to a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, comprising measuring the miRNA(s) in vitro.Type: GrantFiled: February 13, 2020Date of Patent: November 1, 2022Assignees: Toray Industries, Inc., National Cancer CenterInventors: Satoko Kozono, Hitoshi Nobumasa, Satoshi Kondou, Hiroko Sudo, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
-
Patent number: 11486007Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.Type: GrantFiled: June 3, 2015Date of Patent: November 1, 2022Assignees: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTDInventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
-
Patent number: 11479822Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: February 21, 2020Date of Patent: October 25, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Satoshi Kondou, Hitoshi Nobumasa, Satoko Kozono, Hiroko Sudo, Junpei Kawauchi, Takahiro Ochiya, Nobuyoshi Kosaka, Makiko Ono, Kenji Tamura
-
Patent number: 11479821Abstract: It is intended to provide a kit or a device for the detection of colorectal cancer and a method for detecting colorectal cancer. The present invention provides a kit or a device for the detection of colorectal cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting colorectal cancer, comprising measuring the miRNA in vitro.Type: GrantFiled: February 13, 2020Date of Patent: October 25, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Satoko Kozono, Hitoshi Nobumasa, Satoshi Kondou, Hiroko Sudo, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
-
Patent number: 11473143Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.Type: GrantFiled: July 28, 2017Date of Patent: October 18, 2022Assignees: The University of Melbourne, Central Adelaide Local Health Network Incorporated, Itek Ventures PTY Ltd (University of South Australia)Inventors: Sarah Elizabeth Heron, Leanne Michelle Dibbens, Samuel Frank Berkovic, Ingrid Eileen Scheffer, John Charles Mulley
-
Patent number: 11453914Abstract: Provided are methods for detecting or diagnosing a traumatic brain injury or TBI by detecting concentration levels miRNAs associated with TBI in saliva. Methods for controlled and normalized comparisons of salivary miRNA concentration levels are further provided. Assay kits comprising salivary miRNAs, probes and/or primers for detecting salivary miRNAs are also provided.Type: GrantFiled: March 23, 2018Date of Patent: September 27, 2022Assignees: QUADRANT BIOSCIENCES INC., THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, PENN STATE RESEARCH FOUNDATIONInventors: Steven D. Hicks, Frank A. Middleton, Richard Uhlig
-
Patent number: 11441191Abstract: The present invention relates to refined prognostic clinical tools, methods, and kits for the evaluation of risk and treatment of distant recurrence in ER+/HER2? breast cancer patients.Type: GrantFiled: June 19, 2017Date of Patent: September 13, 2022Assignees: Istituto Europeo di Oncologia S.r.l., Fondazione Istituto Firc di Oncologia Molecolare (IFOM), University of MilanInventors: Pier Paolo Di Fiore, Salvatore Pece, Manuela Vecchi, Stefano Confalonieri